Lapatinib for inflammatory breast cancer

被引：3
作者：
Hall, Peter S. [1 ]
Hanby, Andrew [2 ]
Cameron, David A. [3 ]
机构：
[1] Univ Leeds, Sect Oncol & Clin Res, Leeds, W Yorkshire, England
[2] Univ Leeds, Sect Pathol & Tumour Biol, Leeds, W Yorkshire, England
[3] Univ Leeds, Natl Canc Res Network, Leeds, W Yorkshire, England
来源：
LANCET ONCOLOGY | 2009年 / 10卷 / 06期
关键词：
END RESULTS PROGRAM; CARCINOMA INCIDENCE; SURVIVAL; SURVEILLANCE; EPIDEMIOLOGY; EXPRESSION; INSTITUTE; TRENDS;
D O I：
10.1016/S1470-2045(09)70120-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：538 / 539
页数：2
相关论文
共 12 条
  • [1] Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin
    Ben Hamida, Azza
    Labidi, Intidhar S.
    Mrad, Karima
    Charafe-Jauffret, Emmanuelle
    Ben Arab, Saida
    Esterni, Benjamin
    Xerri, Luc
    Viens, Patrice
    Bertucci, Francois
    Birnbaum, Daniel
    Jacquemier, Jocelyne
    [J]. BMC CANCER, 2008, 8 (1)
  • [2] Chang S, 1998, CANCER, V82, P2366
  • [3] Defining the molecular biology of inflammatory breast cancer
    Charafe-Lauffret, Emmanuelle
    Tarpin, Corole
    Viens, Patrice
    Bertucci, Francois
    [J]. SEMINARS IN ONCOLOGY, 2008, 35 (01) : 41 - 50
  • [4] Cristofanilli M, 2006, BREAST CANCER RES TR, V100, pS5
  • [5] Pathologic aspects of inflammatory breast cancer: Part 2. Biologic insights into its aggressive phenotype
    Gong, Yun
    [J]. SEMINARS IN ONCOLOGY, 2008, 35 (01) : 33 - 40
  • [6] Trends for inflammatory breast cancer:: Is survival improving?
    Gonzalez-Angulo, Ana M.
    Hennessy, Bryan T.
    Broglio, Kristine
    Meric-Bernstam, Funda
    Cristofanilli, Massimo
    Giordano, Sharon H.
    Buchholz, Thomas A.
    Sahin, Aysegul
    Singletary, S. Eva
    Buzdar, Aman U.
    Hortobagyi, Gabriel N.
    [J]. ONCOLOGIST, 2007, 12 (08) : 904 - 912
  • [7] Greene FL, 2002, AJCC CANC STAGING MA, P255
  • [8] Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute
    Hance, KW
    Anderson, WF
    Devesa, SS
    Young, HA
    Levine, PH
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (13): : 966 - 975
  • [9] Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+cohort in EGF103009, a phase II study
    Kaufman, Bella
    Trudeau, Maureen
    Awada, Ahmad
    Blackwell, Kimberly
    Bachelot, Thomas
    Salazar, Vanessa
    DeSilvio, Michelle
    Westlund, Ronald
    Zaks, Tal
    Spector, Neil
    Johnston, Stephen
    [J]. LANCET ONCOLOGY, 2009, 10 (06) : 581 - 588
  • [10] Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients
    Konecny, GE
    Meng, YG
    Untch, M
    Wang, HJ
    Bauerfeind, I
    Epstein, M
    Stieber, P
    Vernes, JM
    Gutierrez, J
    Hong, K
    Beryt, M
    Hepp, H
    Slamon, DJ
    Pegram, MD
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (05) : 1706 - 1716
12